CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 80 enrolled
Drug / intervention
18F-FDG +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04417998
NCT04417998Phase 4Completed
CompareCT.gov

Improving PET Image Quality and Quantification by Using Motion Correction, Parametric Imaging and MAP Reconstruction

Mayo Clinic·interventional·Posted Jun 5, 2020·Updated Jan 22, 2025

In Brief

A Phase 4 clinical trial evaluating 18F-FDG, 18F-AV1451, and 1 other intervention for Brain Imaging and Whole Body Imaging. Completed, enrolled 80 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the effectiveness of new software available on a new PET/CT scanner in the Molecular Imaging Research PET/CT Facility. Further, the study aims to evaluate the data acquisition and image processing workflow.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Imaging, Whole Body Imaging
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJun 5, 2020
Enrollment StartJun 3, 2020
Primary CompletionDec 20, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.1 years ago

Interventions

18F-FDGdrug

A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.

18F-AV1451drug

A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.

Siemens E7 Reconstruction Tooldevice

Software to correct for motion